The Safety Review Committee approved enrollment of the next higher-dose cohorts as follows: Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

在全球范围内， 默沙东的Gardasil系列产品的销售额与去年相比下降了11%至23亿美元。默沙东首席执行官Robert Davis在周四举行的第三季度电话会议上指出， 这一下滑是由于中国市场需求减少所致，而这抵消了“几乎所有其他地区”的两位数增长。

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

▎药明康德内容团队编辑mRNA癌症疫苗联合Keytruda治疗更早期肺癌，默沙东/Moderna启动3期临床试验默沙东公司（MSD）与Moderna公司今日宣布启动INTerpath-009试验，这是一项关键性3期临床试验，旨在评估在研个体化新抗原疗 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

基于此前已获批的9项适应症，近期K药针对围手术期局部晚期头颈鳞癌的KEYNOTE-689研究也取得了积极结果，且默沙东已计划提交该适应症的上市申请。这有望成为Keytruda获批的第10项早期癌症适应症。

默沙东集团在2024年第三季度财报电话会议上展现了韧性和适应性,在应对市场挑战的同时,明确专注于增长和创新。公司的战略投资和多元化研发管线表明其致力于满足未满足的医疗需求并提升股东价值。随着默沙东集团继续扩大产品组合并抓住市场机遇,它仍然是全球医疗保 ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...